[Skip to Content]
[Skip to Content Landing]
Views 141
Citations 0
Comment & Response
August 2017

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer

Author Affiliations
  • 1Department of Clinical Science, University of Bergen, Bergen, Norway
  • 2Department of Oncology, Haukeland University Hospital, Bergen, Norway
JAMA Oncol. 2017;3(8):1140. doi:10.1001/jamaoncol.2016.7123

To the Editor In a recent article, Melisko et al1 reported vaginal estradiol to cause little increase in plasma estradiol levels during treatment with aromatase inhibitors. Their data raise some concerns.

First, they found plasma estradiol levels greater than 10 pg/mL, a value in the upper range for untreated postmenopausal women,2,3 in 28 of 76 patients despite treatment with an aromatase inhibitor. For some patients, estradiol levels were greater than 50 pg/mL, inconsistent with a postmenopausal status.

First Page Preview View Large
First page PDF preview
First page PDF preview
×